The novel fixed-dose drug combination of mometasone furoate
and formoterol fumarate (MF/F) may have the same efficacy as that of the commonly
prescribed fluticasone propionate/salmeterol (FP/S) combination in the
treatment of asthma. MF/F has a quicker onset of action compared with FP/S.
Asthma is a chronic
inflammatory disease that causes the airways to swell and narrow. It results in recurrent coughing, chest
tightness, wheezing, and breathlessness.
More than 300
million people worldwide suffer from asthma, with over 80% of related deaths
reported from low and lower-middle income countries. Asthma is a leading cause
of morbidity and mortality in rural India.
of persistent asthma are relieved by inhaled corticosteroid (ICS) drugs. When
these drugs cannot control asthma alone, another category of drugs called
(LABA) like salmeterol and formoterol is added. Mometasone furoate/formoterol is the most recent ICS/LABA combination
therapy available for treating persistent asthma.
most of the previous studies tested the safety profile of this combination
therapy, none evaluated the efficacy in comparison with the commonly prescribed
fluticasone propionate/salmeterol (FP/S) combination. MF/F is well tolerated
and has a safety profile similar to FP/S.
published study was a 12-week long multicenter trial in patients with
uncontrolled persistent asthma previously treated with medium-dose ICS with or
without a LABA. Factors assessed included lung function, asthma control,
quality of life and symptoms, clinically-judged asthma deteriorations, and
safety. (Asthma resulting in emergency treatment, hospitalization, or treatment
with additional drugs defines clinically-judged asthma deteriorations.)
indicate that MF/F improves lung function and asthma control similar to FP/S.
It also has a superior onset of action compared with FP/S.
A faster onset
of action is a highly desired characteristic required in asthma therapy,
especially from a patient perspective. Patients are more likely to stick on to
a medication that works fast and alleviates symptoms soon after initiating
therapy. Treatment satisfaction is a requisite for any modality of disease
management. Significant improvement in lung function was observed 5-30 minutes
after delivery of MF/F via metered-dose inhaler (MDI).
Both the drug combinations are safe,
well tolerated, and improve asthma control. MF/F, however, has a faster onset
of action than FP/S
and Onset of Action of Mometasone Furoate/Formoterol and Fluticasone
Propionate/Salmeterol Combination Treatment in Subjects With Persistent Asthma
Asthma & Clinical Immunology